Atom Grants
Toggle Sidebar main
Eligibility
Profile
Finance
Other
Similar Grants
Platform
Discover
For You
Search
Favorites
Account
Profile
Research Interests
Atom | Drug Development RFP
Back
Drug Development RFP
Rolling Submissions
Alzheimer's Drug Discovery Foundation (ADDF)
$5,000,000
Description
Support for investigational new drug (IND)-enabling studies and early-phase clinical trials testing promising interventions for Alzheimer's disease and related dementias Letter of Intent due on various dates in 2024
Award Ceiling
$5,000,000
Eligible Applicants
- Researchers and clinicians worldwide at academic medical centers
- universities
- nonprofits
- and biotechnology companies
Funding Type
Grant
Categories of Funding Activity
- Science, Technology, and Research & Development
- Health
Grantor Contact Information
Aaron Burstein, PharmD, Head of Search & Evaluation aburstein@alzdiscovery.org
Additional Information
The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias.
Supporting Link
https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-rfp
Start finding grants with Atom for
$0 today
$30 Billed monthly after 7-day trial. Cancel anytime.
Personalized grant emails delivered weekly, right to your inbox.
AI powered search engine with both keyword and semantic search capabilities.
Grant filters to find the perfect funding opportunities.
Get Started
Similar Grants
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Due: Nov 5, 2027
HHS-NIH11
$1,500,000
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Due: Nov 19, 2026
HHS-NIH11
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
Due: Nov 16, 2027
HHS-NIH11